Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Longeveron Inc (LGVN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.71-3.93%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for LGVN yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Reduce operating losses and cash burn to extend runway | The company aims to improve its cash burn and operating losses, which slightly improved from -$5.2M to -$4.8M in early 2026. | Broken | Operating loss or cash burn worsens beyond -$4.8M or -$4.4M | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative growth, driven by the possibility that laromestrocel advances in development for HLHS, a heart condition. The long-term thesis is weakened: clinical delivery and partnering progress are mixed, losses continue, and management execution is described as volatile.
The valuation is expensive versus peers, with an expectations gap tied to the program’s future potential. The evidence labels the pricing as unjustified, but confidence in the valuation model is low, so the precise expectations already reflected in valuation are uncertain.
Near term, losses and cash use remain central: revenue declined between the first and second quarters of 2026, operating losses widened, and cash fell, with the stated runway extending only into 2026-Q4. ELPIS II missed its primary endpoint, though a later update reported a statistically significant secondary MACE endpoint and an FDA discussion is planned; the next report also carries elevated miss risk, and recent litigation adds uncertainty.
Over the multi-year view, the key question is whether the FDA discussion and further clinical work can clarify the mixed ELPIS II results and support development of laromestrocel. Near term, a guidance cut or further cash pressure would add concern, while signed partnerships or stronger Healthcare sector results could provide support; no signed partnership is reported in the evidence.
For the next 1 to 3 years, LGVN remains a speculative, loss-making development story with expensive peer-relative valuation and a weakened thesis. Its central swing factors are clinical clarity, cash runway, and evidence of substantive partnership progress. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Longeveron is focused on advancing laromestrocel therapy with key trial results due in Q3 2026. |
| Improving |
| Top-line results delayed beyond Q3 2026 or negative outcomes |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Resolve Nasdaq listing compliance issues | Management is working to fix Nasdaq listing issues. | Intact | Continued Nasdaq non-compliance or delisting notices beyond 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.46 → $-5.80 · observed estimates
$0.01B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.46 | $6,195,250 | 3 / 3 |
| 2026-07-25 | $-0.46 | $6,195,250 | 3 / 3 |
| 2026-07-26 | $-0.46 | $6,195,250 | 3 / 3 |
| 2026-07-27 | $-0.46 | $6,195,250 | 3 / 3 |
| 2026-07-28 | $-0.46 | $6,195,250 | 3 / 3 |
| 2026-07-29 | $-0.46 | $6,195,250 | 3 / 3 |
| 2026-07-30 | $-0.46 | $6,525,750 | 4 / 4 |
| 2026-07-31 | $-0.46 | $6,525,750 | 4 / 4 |
| 2026-08-01 | $-0.46 | $6,195,250 | 3 / 3 |
| 2026-08-02 | $-0.46 | $6,525,750 | 4 / 4 |
| 2026-08-03 | $-0.46 | $6,525,750 | 4 / 4 |
| 2026-08-04 | $-0.46 | $6,525,750 | 4 / 4 |
| 2026-08-05 | $-0.46 | $6,525,750 | 4 / 4 |
| 2026-08-06 | $-0.46 | $6,525,750 | 4 / 4 |
| 2026-08-07 | $-0.46 | $6,195,250 | 3 / 3 |
| 2026-08-08 | $-0.46 | $6,525,750 | 4 / 4 |
| 2026-08-09 | $-0.46 | $6,525,750 | 4 / 4 |
| 2026-08-10 | $-0.46 | $6,195,250 | 3 / 3 |
| 2026-08-12 | $-0.46 | $6,525,750 | 4 / 4 |
| 2026-08-13 | $-0.46 | $6,195,250 | 3 / 3 |
| 2026-08-14 | $-0.46 | $6,195,250 | 3 / 3 |
| 2026-08-15 | $-0.46 | $6,195,250 | 3 / 3 |
| 2026-08-16 | $-0.46 | $6,195,250 | 3 / 3 |
| 2026-08-17 | $-0.46 | $6,195,250 | 3 / 3 |
| 2026-08-18 | $-0.46 | $6,195,250 | 3 / 3 |
| 2026-08-19 | $-0.46 | $6,195,250 | 3 / 3 |
| 2026-08-20 | $-0.47 | $6,194,250 | 3 / 2 |
| 2026-08-21 | $-0.47 | $6,194,250 | 3 / 3 |
| 2026-08-22 | $-0.47 | $6,194,250 | 3 / 3 |
| 2026-08-23 | $-0.47 | $6,194,250 | 3 / 3 |
| 2026-08-24 | $-0.47 | $7,592,333 | 3 / 3 |
| 2026-08-25 | $-0.47 | $7,592,333 | 3 / 3 |
| 2026-08-26 | $-0.47 | $7,592,333 | 3 / 3 |
| 2026-08-27 | $-0.47 | $7,592,333 | 3 / 3 |
| 2026-08-28 | $-0.47 | $7,592,333 | 3 / 3 |
| 2026-08-29 | $-4.67 | $7,592,333 | 3 / 3 |
| 2026-08-30 | $-4.67 | $7,592,333 | 3 / 3 |
| 2026-08-31 | $-4.67 | $7,592,333 | 3 / 3 |
| 2026-09-01 | $-4.67 | $7,592,333 | 3 / 3 |
| 2026-09-02 | $-4.67 | $7,592,333 | 3 / 3 |
| 2026-09-03 | $-4.67 | $7,592,333 | 3 / 3 |
| 2026-09-04 | $-4.67 | $7,592,333 | 3 / 3 |
| 2026-09-05 | $-4.67 | $7,592,333 | 3 / 3 |
| 2026-09-06 | $-4.67 | $7,592,333 | 3 / 3 |
| 2026-09-07 | $-4.67 | $7,592,333 | 3 / 3 |
| 2026-09-08 | $-4.67 | $7,592,333 | 3 / 3 |
| 2026-09-09 | $-4.67 | $7,592,333 | 3 / 3 |
| 2026-09-10 | $-4.67 | $7,592,333 | 3 / 3 |
| 2026-09-11 | $-4.67 | $7,592,333 | 3 / 3 |
| 2026-09-12 | $-4.67 | $7,592,333 | 3 / 3 |
| 2026-09-13 | $-4.67 | $7,592,333 | 3 / 3 |
| 2026-09-14 | $-4.67 | $7,592,333 | 3 / 3 |
| 2026-09-15 | $-4.67 | $7,592,333 | 3 / 3 |
| 2026-09-16 | $-4.67 | $7,592,333 | 3 / 3 |
| 2026-09-17 | $-4.67 | $7,592,333 | 3 / 3 |
| 2026-09-18 | $-4.67 | $7,592,333 | 3 / 3 |
| 2026-09-19 | $-4.67 | $7,592,333 | 3 / 3 |
| 2026-09-20 | $-5.00 | $11,388,500 | 3 / 3 |
| 2026-09-21 | $-5.00 | $11,388,500 | 2 / 3 |
| 2026-09-22 | $-5.00 | $11,388,500 | 2 / 3 |
| 2026-09-23 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-09-24 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-09-25 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-09-26 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-09-27 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-09-28 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-09-29 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-09-30 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-10-01 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-10-02 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-10-03 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-10-04 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-10-05 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-10-06 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-10-07 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-10-08 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-10-09 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-10-10 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-10-11 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-10-12 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-10-13 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-10-14 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-10-15 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-10-16 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-10-17 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-10-18 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-10-19 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-10-20 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-10-21 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-10-22 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-10-23 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-10-24 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-10-25 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-10-26 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-10-27 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-10-28 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-10-29 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-10-30 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-10-31 | $-5.00 | $11,388,500 | 2 / 2 |
| 2026-11-01 | $-5.80 | $2,368,000 | 2 / 2 |
| 2026-11-02 | $-5.80 | $2,368,000 | 1 / 1 |
| 2026-11-03 | $-5.80 | $2,368,000 | 1 / 1 |
| 2026-11-04 | $-5.80 | $2,368,000 | 1 / 1 |
| 2026-11-05 | $-5.80 | $2,368,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.